MEDICAL SERVICES

EDUCATION

Undergraduate Degree

  • Barnard College, Columbia University , 1994 , New York , NY

Medical School

  • Harvard Medical School , 2000 , Boston , MA

Internship

Medicine
  • Boston Children's Hospital , 2001 , Boston , MA

Residency

Pediatrics
  • Boston Combined Residency Program (BCRP) , 2003 , Boston , MA

Fellowship

Pediatric Hematology-Oncology
  • Boston Children's Hospital and Dana-Farber Cancer Institute , 2007 , Boston , MA

Graduate Degree

MMSc
  • Harvard Medical School , 2008 , Boston , MA

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Patterns of Translocation Testing in Patients Enrolling to a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. Arch Pathol Lab Med. 2021 Mar 26. View abstract
  2. Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. Cancer Med. 2021 Mar 09. View abstract
  3. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-risk Leukemias: A Report from the LEAP Consortium. Cancer Discov. 2021 Feb 09. View abstract
  4. OncoTree: A Cancer Classification System for Precision Oncology. JCO Clin Cancer Inform. 2021 Feb; 5:221-230. View abstract
  5. Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors. Cancer Chemother Pharmacol. 2021 May; 87(5):621-634. View abstract
  6. A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: Opportunities for precision medicine. Pediatr Blood Cancer. 2021 Apr; 68(4):e28780. View abstract
  7. Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children's Oncology Group. Sarcoma. 2020; 2020:3498549. View abstract
  8. Derivation and validation of risk groups in patients with osteosarcoma utilizing regression tree analysis. Pediatr Blood Cancer. 2021 Mar; 68(3):e28834. View abstract
  9. Desmoid tumors of the head and neck in the pediatric population: Has anything changed? Int J Pediatr Otorhinolaryngol. 2021 Jan; 140:110511. View abstract
  10. PD-1 and PD-L1 Expression in Osteosarcoma: Which Specimen to Evaluate? J Pediatr Hematol Oncol. 2020 11; 42(8):482-487. View abstract
  11. Phase I/II Study of Stereotactic Body Radiation Therapy for Pulmonary Metastases in Pediatric Patients. Adv Radiat Oncol. 2020 Nov-Dec; 5(6):1267-1273. View abstract
  12. Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases. Pediatr Blood Cancer. 2020 10; 67(10):e28636. View abstract
  13. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 10; 67(10):e28559. View abstract
  14. Making the most of small samples: Optimization of tissue allocation of pediatric solid tumors for clinical and research use. Pediatr Blood Cancer. 2020 09; 67(9):e28326. View abstract
  15. Recurrent RET gene fusions in paediatric spindle mesenchymal neoplasms. Histopathology. 2020 Jun; 76(7):1032-1041. View abstract
  16. DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol. 2020 10; 33(10):1910-1921. View abstract
  17. Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. Clin Cancer Res. 2020 06 15; 26(12):2882-2890. View abstract
  18. Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers. J Natl Cancer Inst. 2020 03 01; 112(3):224-228. View abstract
  19. Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. Clin Cancer Res. 2020 04 15; 26(8):1837-1845. View abstract
  20. A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. Thyroid. 2019 11; 29(11):1704-1707. View abstract
  21. Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group. Cardiooncology. 2019; 5:15. View abstract
  22. The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. Oncologist. 2020 01; 25(1):e39-e47. View abstract
  23. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group. Eur J Cancer. 2019 11; 121:177-183. View abstract
  24. A Distinctive Genomic and Immunohistochemical Profile for NOTCH3 and PDGFRB in Myofibroma With Diagnostic and Therapeutic Implications. Int J Surg Pathol. 2020 Apr; 28(2):128-137. View abstract
  25. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol. 2019 12 01; 37(34):3192-3202. View abstract
  26. Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. Cancer. 2019 10 15; 125(20):3514-3525. View abstract
  27. Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2. Commun Biol. 2019; 2:266. View abstract
  28. Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2. Commun Biol. 2019 Jul 19; 2(1):266. View abstract
  29. Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial. Cancer Chemother Pharmacol. 2019 07; 84(1):41-50. View abstract
  30. Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. F1000Res. 2019; 8. View abstract
  31. Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2019 Apr; 120(8):869. View abstract
  32. Ushering in the next generation of precision trials for pediatric cancer. Science. 2019 Mar 15; 363(6432):1175-1181. View abstract
  33. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 03 12; 8. View abstract
  34. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019 03; 109:36-50. View abstract
  35. Duality of purpose: Participant and parent understanding of the purpose of genomic tumor profiling research among children and young adults with solid tumors. JCO Precis Oncol. 2019; 3. View abstract
  36. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma. Clin Cancer Res. 2019 02 15; 25(4):1343-1357. View abstract
  37. A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2019 02; 66(2):e27524. View abstract
  38. Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2019 01; 66(1):e27444. View abstract
  39. Dose Intensification Improves the Outcome of Ewing Sarcoma. J Clin Oncol. 2018 Sep 12; JCO2018793489. View abstract
  40. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2018 08; 119(5):615-621. View abstract
  41. Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches. Sarcoma. 2018; 2018:1712964. View abstract
  42. Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2018; 2018. View abstract
  43. Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. JCO Precis Oncol. 2018; 2018. View abstract
  44. Precision medicine in pediatric oncology. Curr Opin Pediatr. 2018 02; 30(1):17-24. View abstract
  45. Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma. Pediatr Blood Cancer. 2018 04; 65(4). View abstract
  46. Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2018 03; 31(3):463-473. View abstract
  47. Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2017 12 01; 99(5):1286-1294. View abstract
  48. Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children's Oncology Group and the QuadW Foundation. PLoS One. 2017; 12(7):e0181204. View abstract
  49. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 2017 Jul 01; 19(7):986-996. View abstract
  50. Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res. 2017 Jun 15; 23(12):e68-e75. View abstract
  51. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res. 2017 06 01; 23(11):e38-e45. View abstract
  52. An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets. J Hematol Oncol. 2017 05 15; 10(1):107. View abstract
  53. Clinical trial enrollment of adolescents and young adults with sarcoma. Cancer. 2017 Sep 15; 123(18):3434-3440. View abstract
  54. Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. J Natl Cancer Inst. 2017 05 01; 109(5). View abstract
  55. Molecular profiling in the clinic: Moving from feasibility assessment to evaluating clinical impact. Pediatr Blood Cancer. 2017 06; 64(6). View abstract
  56. Pediatric oncology enters an era of precision medicine. Curr Probl Cancer. 2017 May - Jun; 41(3):194-200. View abstract
  57. Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. Cancer Res. 2017 01 15; 77(2):509-519. View abstract
  58. Advances in the Treatment of Pediatric Bone Sarcomas. Am Soc Clin Oncol Educ Book. 2017; 37:725-735. View abstract
  59. Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. J Clin Oncol. 2017 Feb 10; 35(5):523-528. View abstract
  60. Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis. Pediatr Blood Cancer. 2017 Jul; 64(7). View abstract
  61. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062. View abstract
  62. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 Oct; 17(10):1396-1408. View abstract
  63. The case for informative phase 2 trials in osteosarcoma. Lancet Oncol. 2016 08; 17(8):1022-1023. View abstract
  64. Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. Ann Surg Oncol. 2016 12; 23(Suppl 5):990-997. View abstract
  65. Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. Pediatr Blood Cancer. 2016 11; 63(11):1974-82. View abstract
  66. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. J Clin Oncol. 2016 09 01; 34(25):3031-8. View abstract
  67. Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma. F1000Res. 2016; 5. View abstract
  68. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol. 2016 Jul 01; 2(7):922-8. View abstract
  69. Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016 06 22; 7:11987. View abstract
  70. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 May 01; 2(5):608-615. View abstract
  71. Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer. 2016 10; 63(10):1737-43. View abstract
  72. Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. Cancer Genet. 2016 05; 209(5):182-94. View abstract
  73. Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. Clin Cancer Res. 2016 07 15; 22(14):3643-50. View abstract
  74. Future directions in the treatment of osteosarcoma. Curr Opin Pediatr. 2016 Feb; 28(1):26-33. View abstract
  75. Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children's Oncology Group. J Surg Oncol. 2016 Mar; 113(4):351-4. View abstract
  76. Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. Cold Spring Harb Mol Case Stud. 2015 Oct; 1(1):a000471. View abstract
  77. Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2016 Feb; 63(2):370-1. View abstract
  78. Integrity of the pheochromocytoma susceptibility TMEM127 gene in patients with pediatric malignancies. Endocr Relat Cancer. 2015 Jun; 22(3):L5-7. View abstract
  79. Marketing of personalized cancer care on the web: an analysis of Internet websites. J Natl Cancer Inst. 2015 May; 107(5). View abstract
  80. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):E5564-73. View abstract
  81. A summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW Foundation. Pediatr Blood Cancer. 2015 Mar; 62(3):450-5. View abstract
  82. Exploring the association of succinate dehydrogenase complex mutations with lymphoid malignancies. Fam Cancer. 2014 Sep; 13(3):507-11. View abstract
  83. Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res. 2014 Aug 15; 20(16):4200-9. View abstract
  84. HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. Pediatr Blood Cancer. 2014 Sep; 61(9):1558-64. View abstract
  85. Post-transcriptional dysregulation by miRNAs is implicated in the pathogenesis of gastrointestinal stromal tumor [GIST]. PLoS One. 2013; 8(5):e64102. View abstract
  86. Future of clinical genomics in pediatric oncology. J Clin Oncol. 2013 May 20; 31(15):1893-903. View abstract
  87. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 2013 Jun; 3(6):648-57. View abstract
  88. MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32. Genome Med. 2013; 5(1):2. View abstract
  89. Children's Oncology Group's 2013 blueprint for research: bone tumors. Pediatr Blood Cancer. 2013 Jun; 60(6):1009-15. View abstract
  90. New strategies in sarcoma therapy: linking biology and novel agents. Clin Cancer Res. 2012 Nov 01; 18(21):5837-44. View abstract
  91. Treatment guidelines for gastrointestinal stromal tumors in children and young adults. J Pediatr Hematol Oncol. 2012 May; 34 Suppl 2:S69-72. View abstract
  92. Cardiac paraganglioma in an adolescent. Circulation. 2012 Feb 07; 125(5):e322-4. View abstract
  93. Pediatric gastrointestinal stromal tumor. Semin Pediatr Surg. 2012 Feb; 21(1):31-43. View abstract
  94. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. Cancer. 2012 Sep 15; 118(18):4597-605. View abstract
  95. Special considerations in pediatric gastrointestinal tumors. J Surg Oncol. 2011 Dec; 104(8):928-32. View abstract
  96. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res. 2011 Apr 01; 71(7):2686-96. View abstract
  97. Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma. Pediatr Blood Cancer. 2012 Feb; 58(2):181-4. View abstract
  98. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A. 2011 Jan 04; 108(1):314-8. View abstract
  99. Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int J Cancer. 2010 Dec 01; 127(11):2718-22. View abstract
  100. Modeling human osteosarcoma in the mouse: From bedside to bench. Bone. 2010 Nov; 47(5):859-65. View abstract
  101. Pediatric and wild-type gastrointestinal stromal tumor: new therapeutic approaches. Curr Opin Oncol. 2010 Jul; 22(4):347-50. View abstract
  102. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol. 2010 Jul; 11(7):670-8. View abstract
  103. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer. 2009 Jul; 52(7):767-71. View abstract
  104. Pediatric gastrointestinal stromal tumors. Hematol Oncol Clin North Am. 2009 Feb; 23(1):15-34, vii. View abstract
  105. Pediatric GIST. Hematology Oncology Clinics of North America. 2009; 23(1). View abstract
  106. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res. 2007 Oct 01; 67(19):9084-8. View abstract
  107. Neutropenia. Comprehensive Pediatric Hospital Medicine (Zaoutis LB and Chiang VW eds.). 2007; 738-743. View abstract
  108. Successful treatment of pediatric metastatic gastrointestinal stromal tumor (GIST) with Sunitinib after failure of imatinib. Journal of Clinical Oncology. 2006; 24(18s):9519. View abstract
  109. Sunitinib treatment of pediatric metastatic GIST after failure of imatinib. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9519. View abstract
  110. Fever without a source in infants and young children. Boston Combined Residency Program Pediatric Guidebook (Binstadt B and Gupta M eds.). 2001. View abstract
  111. Carpal tunnel syndrome and workers' compensation among an occupational clinic population in New York State. Am J Ind Med. 1999 Apr; 35(4):335-42. View abstract